Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Oil Fund (DBO) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Invesco DB Oil FundTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Oil Fund vs Ginkgo Bioworks Holdings Inc — how do they compare? Invesco DB Oil Fund trades at $23.56 (market cap $255.13M), while Ginkgo Bioworks Holdings Inc trades at $11.99 (market cap $763.64M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.

DBODNA
Market Cap
$255.13M$763.64M
Volume
562,1673,204,177
Sector
Commodities - EnergyHealth
52-Week High
$26.35$15.83
52-Week Low
$11.98$5.48
Typical Hold Time
31 Days7 Days
Enterprise Value
—$865.59M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Oil Fund

DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.

The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.

The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DBO
0% Buy100% Sell
Avg holding period · 31 Days
DNA
53% Buy47% Sell
Avg holding period · 7 Days

Top news

Latest headlines on both assets

About Invesco DB Oil Fund

DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.

Read more on DBO →

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →